Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 3, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Interventions
DRUG

Pembrolizumab

Immunotherapy that works by helping the immune system to kill cancer cells by targeting and blocking a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.

DRUG

Carboplatin

A chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.

DRUG

Paclitaxel

A chemotherapeutic agent used as a treatment for various cancers; paclitaxel is a mitotic inhibitor.

Trial Locations (1)

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

All Listed Sponsors
lead

Dan Zandberg

OTHER